Initiation and Titration of Amaryl (AMIT KZ)
AMIT Study - Amaryl M Initiation and Titration Study
Primary Objective:
- To describe the conditions of initiation and titration of Amaryl M, according to previous treatment:
- initial dose
- titration scheme
- efficacy after 4 months assessed by HbA1C
- tolerability (number and severity of hypoglycaemia)
Secondary Objective:
- Fasting Plasma Glucose
- Weight evolution
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Almaty, Kazakhstan
- Sanofi-Aventis Administrative Office
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Patients with Type 2 diabetes who have been treated with a stable dose (any dose) of :
- sulfonylurea monotherapy or
- metformin monotherapy or
- free combination of glimepiride and metformin with a stable dose (any dose)
- Body Mass Index (BMI) between 20 and 40 kg/m2
- HbA1c superior or egal to 7.5%
- FPG superior or egal 7 mmol/l
Exclusion criteria:
- Secondary or insulin-dependant diabetes
- Any severe chronic disease (hepatic, renal impairments)
- History of major cardiovascular event in the last 6 months
- Acute conditions with the potential to alter renal function such as: dehydratation, severe infection, shock, IV administration of iodinated contrast agents
- Allergy to sulfonylurea, metformin
- Drug or alcohol abuse
- Pregnancy, lactation
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Single arm Glimepiride+metformin
Start and titration based on FBG and tolerance.
Titration should be achieved within maximum 4 weeks.
|
Pharmaceutical form: Tablet Route of administration: oral Dose regimen : fixed dose combination of glimepiride / metformin: 1/250, 2/500
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Glycolysated Haemoglobin (HbA1c)
Time Frame: From baseline to Month 4
|
From baseline to Month 4
|
|
Patients With Glycosylated Haemoglobin (HbA1c) Value < 7%
Time Frame: Month 4
|
Month 4
|
|
Evolution of Fasting Plasma Glucose (FPG)
Time Frame: From baseline to Months 4
|
From baseline to Months 4
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Post Prandial Plasma Glucose (PPPG)
Time Frame: Month 4
|
Month 4
|
|
Number of patients for each start dose
Time Frame: At baseline
|
At baseline
|
|
Number of patients with different final doses
Time Frame: Month 4
|
Month 4
|
|
Rate of Symptomatic Hypoglycemia
Time Frame: During treatment period (4 months)
|
During treatment period (4 months)
|
|
Change in Weight
Time Frame: Month 4
|
Month 4
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GLMET_L_04718
- U1111-1116-9956 (OTHER: UTN)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.